Fluoguide AS
STO:FLUO
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
33.9
75.6
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Fluoguide AS
Total Equity
Fluoguide AS
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
F
|
Fluoguide AS
STO:FLUO
|
Total Equity
kr12.7m
|
CAGR 3-Years
42%
|
CAGR 5-Years
351%
|
CAGR 10-Years
N/A
|
|
Genmab A/S
CSE:GMAB
|
Total Equity
kr31B
|
CAGR 3-Years
15%
|
CAGR 5-Years
30%
|
CAGR 10-Years
33%
|
||
Zealand Pharma A/S
CSE:ZEAL
|
Total Equity
kr8.9B
|
CAGR 3-Years
96%
|
CAGR 5-Years
45%
|
CAGR 10-Years
40%
|
||
Ascendis Pharma A/S
NASDAQ:ASND
|
Total Equity
-€97.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Total Equity
kr10.4B
|
CAGR 3-Years
22%
|
CAGR 5-Years
39%
|
CAGR 10-Years
27%
|
|
Bioporto A/S
CSE:BIOPOR
|
Total Equity
kr104.8m
|
CAGR 3-Years
11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
12%
|
Fluoguide AS
Glance View
FluoGuide A/S engages in the development of surgical solutions to reduce suffering for the patient and increase the likelihood of cure; as well as reducing costs for the health care system. The firm develops surgical solutions, which expected to reduce Cancer pain for the patient and increases the possibility of recovering as well as reducing costs for the health care system. The first product is the compound FG001, which lights up the cancer and its invasive growth into the surrounding tissue.
See Also
What is Fluoguide AS's Total Equity?
Total Equity
12.7m
DKK
Based on the financial report for Dec 31, 2023, Fluoguide AS's Total Equity amounts to 12.7m DKK.
What is Fluoguide AS's Total Equity growth rate?
Total Equity CAGR 5Y
351%
Over the last year, the Total Equity growth was -60%. The average annual Total Equity growth rates for Fluoguide AS have been 42% over the past three years , 351% over the past five years .